LPCN 1148
Alternative Names: LPCN-1148Latest Information Update: 03 Jun 2025
At a glance
- Originator Lipocine
 - Class Anabolic steroids; Androstenols; Hepatoprotectants; Hormonal replacements; Small molecules; Testosterone congeners
 - Mechanism of Action Androgen receptor agonists; Testosterone replacements
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity No
 - Available For Licensing Yes - Liver cirrhosis
 
Highest Development Phases
- Phase II Liver cirrhosis; Sarcopenia
 - No development reported Non-alcoholic fatty liver disease
 
Most Recent Events
- 17 Dec 2024 LPCN 1148 receives Fast Track designation for Sarcopenia [PO,Capsule] in USA
 - 28 Aug 2024 No recent reports of development identified for phase-I development in Non-alcoholic-fatty-liver-disease in USA (PO)
 - 05 Jun 2024 Efficacy and adverse events data from the phase II trial in Liver cirrhosis was presented at European Association for the Study of the Liver Congress 2024 (EASL-2024)